Resection of colorectal liver metastases (CRLM) is potentially curative therapy when used as part of multimodality therapy. For more than 2 decades, we have known that metastasectomy for CRLM provides a survival advantage. Although the value of resection has never been established by a randomized clinical trial, the weight of the evidence from large case series and population studies involving thousands of patients is overwhelming in favor of resection. Furthermore, the benefit is large; the 5-year overall survival of patients with resection of CRLM is greater than 50%,1 compared with approximately 14% in patients treated with chemotherapy.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wei AC, Jarnagin WR. Questioning Why More Patients With Colorectal Liver Metastases Are Not Referred for Metastasectomy. JAMA Surg. 2020;155(10):909–910. doi:10.1001/jamasurg.2020.1460
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.